Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Bendamustine-bortezomib-dexamethasone in heavily pretreated immunotherapy-refractory myeloma

Claudio Cerchione • 10 Jun 2022
EHA 2022
Multiple Myeloma Bortezomib Dexamethasone

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, talks on the efficacy of the combination of bendamustine, bortezomib, and dexamethasone in heavily pretreated immunotherapy-refractory patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Claudio Cerchione

6:48
Key trials in multiple myeloma presented at ASH 2023: take home messages
Claudio Cerchione • 11 Dec 2023
4:58
Novel immunotherapies transforming R/R myeloma treatment: bispecifics, CAR-T cells & more
Claudio Cerchione • 28 Sep 2023
3:15
Promising triplets and agents in R/R myeloma: SVd, Isa-Kd and melflufen
Claudio Cerchione • 28 Sep 2023
2:34
The role of FDG-PET plus whole body MRI in staging patients with high-risk SMM & R/R myeloma
Claudio Cerchione • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals